199 related articles for article (PubMed ID: 35657013)
1. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
Pearl M; Weng PL; Chen L; Dokras A; Pizzo H; Garrison J; Butler C; Zhang J; Reed EF; Kim IK; Choi J; Haas M; Zhang X; Vo A; Chambers ET; Ettenger R; Jordan S; Puliyanda D
Clin Transplant; 2022 Aug; 36(8):e14734. PubMed ID: 35657013
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients.
Khairallah P; Robbins-Juarez S; Patel S; Shah V; Toma K; Fernandez H; Dube GK; King K; Mohan S; Husain SA; Morris H; Crew RJ
Clin Transplant; 2023 Jan; 37(1):e14853. PubMed ID: 36398915
[TBL] [Abstract][Full Text] [Related]
5. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
[TBL] [Abstract][Full Text] [Related]
7. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
[TBL] [Abstract][Full Text] [Related]
8. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
Boonpheng B; De Castro ICC; Ng YH; Blosser C; Bakthavatsalam R; Gimferrer I; Smith K; Leca N
Clin Transplant; 2023 May; 37(5):e14936. PubMed ID: 36787372
[TBL] [Abstract][Full Text] [Related]
10. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Antibody-Mediated Rejection After Kidney Transplantation: Immunological Effects, Clinical Response, and Histological Findings.
de Sousa MV; Gonçalez AC; de Lima Zollner R; Mazzali M
Ann Transplant; 2020 Nov; 25():e925488. PubMed ID: 33199675
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
14. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
[TBL] [Abstract][Full Text] [Related]
15. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological analyses of transplant glomerulopathy cases.
Shimizu T; Ishida H; Toki D; Nozaki T; Omoto K; Tanabe K; Honda K; Koike J
Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab for antibody-mediated rejection treatment in lung transplantation.
January SE; Fester KA; Halverson LP; Witt CA; Byers DE; Vazquez-Guillamet R; Alexander-Brett J; Tague LK; Kreisel D; Gelman A; Puri V; Bahena RN; Takahashi T; Hachem RR; Kulkarni HS
J Heart Lung Transplant; 2023 Oct; 42(10):1353-1357. PubMed ID: 37268051
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients.
Bujnowska A; Michon M; Konopelski P; Hryniewiecka E; Jalbrzykowska A; Perkowska-Ptasinska A; Cieciura T; Zagozdzon R; Paczek L; Ciszek M
Transplant Proc; 2018; 50(6):1720-1725. PubMed ID: 29961551
[TBL] [Abstract][Full Text] [Related]
19. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
Parajuli S; Joachim E; Alagusundaramoorthy S; Blazel J; Aziz F; Garg N; Muth B; Mohamed M; Mandelbrot D; Zhong W; Djamali A
Transplantation; 2019 Aug; 103(8):1722-1729. PubMed ID: 30507740
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
Ginevri F; Nocera A; Comoli P; Innocente A; Cioni M; Parodi A; Fontana I; Magnasco A; Nocco A; Tagliamacco A; Sementa A; Ceriolo P; Ghio L; Zecca M; Cardillo M; Garibotto G; Ghiggeri GM; Poli F
Am J Transplant; 2012 Dec; 12(12):3355-62. PubMed ID: 22959074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]